Theseus Pharmaceuticals, Inc. – NASDAQ:THRX

Add to watchlist

Market closed

Open in 3 days

+0.74%

month

+91.51%

quarter

-67.02%

year

Market Cap	181.49M
Enterprise value	294.27M

P/E	-6.99
EV/Sales	N/A
EV/EBITDA	-5.82
Price/Sales	N/A
Price/Book	1.85
PEG ratio	-0.12
EPS	-1.33

Revenue	N/A
EBITDA	-66.50M
Income	-55.85M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX): Profit margin
Dec 2022	0	-15.43M
Mar 2023	0	-12.11M
Jun 2023	0	-14.80M
Sep 2023	0	-13.50M

Theseus Pharmaceuticals Financials Estimate

Q Y

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX): Analyst Estimates
2025	0	-88.55M

Analysts Price target
Financials & Ratios estimates

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX): Earnings per share (EPS)
2023-11-17	-0.35	-0.31
2024-03-14	-0.33	-0.35

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX): Debt to assets
Dec 2022	222447000	14.83M	6.67%
Mar 2023	255620000	10.13M	3.96%
Jun 2023	245071000	10.98M	4.48%
Sep 2023	234627000	10.10M	4.31%

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX): Cash Flow
Dec 2022	-9.93M	-11.13M	112
Mar 2023	-18.63M	-15.76M	49.48M
Jun 2023	-10.03M	-51.93M	142K
Sep 2023	-11.02M	10.07M	0

Theseus Pharmaceuticals alternative data

Theseus Pharmaceuticals
Employees

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX): Employee count
Aug 2023	38
Sep 2023	38
Oct 2023	38
Nov 2023	38
Dec 2023	38
Jan 2024	38
Feb 2024	38
Mar 2024	38
Apr 2024	38
May 2024	38
Jun 2024	38
Jul 2024	38

Theseus Pharmaceuticals
Hedge Funds Holdings Q1 2023

20.33% -65.45%

of THRX is owned by hedge funds

29 -19

hedge funds hold THRX stock

7.82M -25.27M

shares is hold by hedge funds

THRX hedge funds holdings changes

Theseus Pharmaceuticals
Insider Trading

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX): Insider trades (number of shares)
Period	Buy	Sel
Nov 2022	388002	0
Dec 2022	510000	0
Jul 2023	1659864	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	6 Nov 2023	SHAKESPEARE WILLIAM officer: See Rema..	Common Stock	251,084	$0.32	$80,347
Option	6 Nov 2023	SHAKESPEARE WILLIAM officer: See Rema..	Stock Option (right to buy)	251,084	$0.32	$80,347
Purchase	17 Jul 2023	GORDON CARL L director, 10 percent owner: director, 10 percent owner:	Common Stock	328,482	$3.05	$1,001,870
Purchase	17 Jul 2023	GORDON CARL L director, 10 percent owner: director, 10 percent owner:	Common Stock	151,450	$3.05	$461,923
Purchase	17 Jul 2023	ORBIMED ADVISORS LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	328,482	$3.05	$1,001,870
Purchase	17 Jul 2023	ORBIMED ADVISORS LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	151,450	$3.05	$461,923
Purchase	17 Jul 2023	FORESITE CAPITAL MANAGEMENT V, LLC 10 percent owner 10 percent owner	Common Stock	523,450	$2.97	$1,554,647
Purchase	17 Jul 2023	FORESITE CAPITAL MANAGEMENT V, LLC 10 percent owner 10 percent owner	Common Stock	176,550	$2.97	$524,354
Purchase	30 Dec 2022	HAYDEN DONALD J JR director director	Common Stock	9,900	$5	$49,490
Purchase	29 Dec 2022	FORESITE CAPITAL MANAGEMENT V, LLC 10 percent owner 10 percent owner	Common Stock	250,000	$5	$1,250,000

THRX insider trading transactions

Theseus Pharmaceuticals
Executives

Insider	Age	Compensation
Dr. William C. Shakespeare Ph.D. (1963) Co-Founder and Pres of R&D	62	$323,240
Dr. Victor M. Rivera Ph.D. (1964) Co-Founder, Senior Vice President & Chief Scientific Officer	61	$313,940
Dr. David C. Dalgarno Ph.D. (1958) Co-Founder, Senior Vice President & Chief Technology Officer	67	$313,940
Dr. Iain D. Dukes D.Phil., M.A., Ph.D. (1958) Co-Founder & Chairman	67	$183,000

Theseus Pharmaceuticals
Latest News

Wednesday, 14 February 2024
08:30	Theseus Pharmaceuticals Announces Closing of Tender Offer	prnewswire.com
Monday, 22 January 2024
15:41	THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX	prnewswire.com
Friday, 29 December 2023
10:32	Is Theseus Pharmaceuticals (THRX) Stock a Solid Choice Right Now?	Zacks Investment Research
Monday, 27 November 2023
11:17	Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan	Zacks Investment Research
Friday, 29 September 2023
07:35	Theseus Pharmaceuticals: Picking Up The Pieces After A Lead Failure	Seeking Alpha
Friday, 11 August 2023
10:47	Down -65.65% in 4 Weeks, Here's Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)	Zacks Investment Research
Wednesday, 19 July 2023
09:52	New Strong Buy Stocks for July 19th	Zacks Investment Research
Tuesday, 18 July 2023
11:21	After Plunging -69.57% in 4 Weeks, Here's Why the Trend Might Reverse for Theseus Pharmaceuticals, Inc. (THRX)	Zacks Investment Research
Monday, 17 July 2023
12:02	Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study	Zacks Investment Research
Friday, 14 July 2023
08:46	Why Is Theseus Pharmaceuticals (THRX) Stock Down 68% Today?	InvestorPlace
Thursday, 13 July 2023
19:11	Why These 2 Biotech Stocks Made Big Moves Late Thursday	The Motley Fool
17:14	Theseus Pharmaceuticals stock plummets after cancer drug development stopped	Market Watch
Tuesday, 4 April 2023
11:24	Wall Street Analysts See a 128.83% Upside in Theseus Pharmaceuticals, Inc. (THRX): Can the Stock Really Move This High?	Zacks Investment Research
Tuesday, 21 March 2023
13:00	4 Biotech Stocks to Consider for Your Portfolio in 2023	Zacks Investment Research
Tuesday, 14 March 2023
13:44	What Makes Theseus Pharmaceuticals, Inc. (THRX) a New Buy Stock	Zacks Investment Research
Monday, 13 February 2023
22:51	The 5 Best and Worst Performing Small-Cap Stocks in January 2023	24/7 Wall Street
Tuesday, 8 March 2022
17:01	Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting	PRNewsWire
Wednesday, 9 February 2022
07:30	Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference	PRNewsWire
Tuesday, 18 January 2022
14:56	Top Stocks To Invest In Right Now? 5 Health Care Stocks To Watch	Stockmarketcom
Monday, 27 December 2021
11:12	5 Beaten Down Biotech Stocks That Could Bounce Big In 2022	Benzinga

Ideas & Opinions

Seeking Alpha 29 Sep 2023

Theseus Pharmaceuticals: Picking Up The Pieces After A Lead Failure
Seeking Alpha 27 Apr 2023

Theseus Pharmaceuticals: Orbimed-Backed Ex-ARIAD Team Developing Next-Gen TKI

Frequently Asked Questions (FAQ)

When is Theseus Pharmaceuticals's next earnings date?

Unfortunately, Theseus Pharmaceuticals's (THRX) next earnings date is currently unknown.
Does Theseus Pharmaceuticals pay dividends?

No, Theseus Pharmaceuticals does not pay dividends.
How much money does Theseus Pharmaceuticals make?

Theseus Pharmaceuticals has a market capitalization of 181.49M. Theseus Pharmaceuticals made a loss 47.08M US dollars in net income (profit) last year or -$0.35 on an earnings per share basis.
What is Theseus Pharmaceuticals's stock symbol?

Theseus Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "THRX".
What is Theseus Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Theseus Pharmaceuticals?

Shares of Theseus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Theseus Pharmaceuticals's key executives?
Theseus Pharmaceuticals's management team includes the following people:
- Dr. William C. Shakespeare Ph.D. Co-Founder and Pres of R&D(age: 62, pay: $323,240)
- Dr. Victor M. Rivera Ph.D. Co-Founder, Senior Vice President & Chief Scientific Officer(age: 61, pay: $313,940)
- Dr. David C. Dalgarno Ph.D. Co-Founder, Senior Vice President & Chief Technology Officer(age: 67, pay: $313,940)
- Dr. Iain D. Dukes D.Phil., M.A., Ph.D. Co-Founder & Chairman(age: 67, pay: $183,000)
Is Theseus Pharmaceuticals founder-led company?

Yes, Theseus Pharmaceuticals is a company led by its founders Dr. William C. Shakespeare Ph.D., Dr. Victor M. Rivera Ph.D., Dr. David C. Dalgarno Ph.D. and Dr. Iain D. Dukes D.Phil., M.A., Ph.D..
How many employees does Theseus Pharmaceuticals have?

As Jul 2024, Theseus Pharmaceuticals employs 38 workers.
When Theseus Pharmaceuticals went public?

Theseus Pharmaceuticals, Inc. is publicly traded company for more then 3 years since IPO on 7 Oct 2021.
What is Theseus Pharmaceuticals's official website?

The official website for Theseus Pharmaceuticals is theseusrx.com.
Where are Theseus Pharmaceuticals's headquarters?

Theseus Pharmaceuticals is headquartered at 245 Main Street, Cambridge, MA.
How can i contact Theseus Pharmaceuticals?

Theseus Pharmaceuticals's mailing address is 245 Main Street, Cambridge, MA and company can be reached via phone at 857 400 9491.

Theseus Pharmaceuticals, Inc.

theseusrx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

857 400 9491

245 Main Street
Cambridge, MA 02142

CIK: 0001745020
ISIN: US88369M1018
CUSIP: 88369M101